James Kelly

James Kelly

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2020 in PLOS Biology
Verified
Journal Article
Open access
PDF file
CCCarina Conceicao
Carina Conceicao
NTNazia Thakur
Nazia Thakur
SHStacey Human
Stacey Human
JKJames Kelly
James Kelly
LLLeanne Logan
Leanne Logan
DBDalan Bailey
Dalan Bailey
SARS Coronavirus 2 (SARS-CoV-2) emerged in late 2019, leading to the Coronavirus Disease 2019 (COVID-19) pandemic that continues to cause significant global mortality in human populations. Given its sequence similarity to SARS-CoV, as well as related coronaviruses circulating in bats, SARS-CoV-2 is thought to have originated in Chiroptera species in China. However, whether the virus spread directly to humans or through an intermediate host is currently unclear, as is the potential for this virus to infect companion animals, livestock, and wildlife that could act as viral reservoirs. Using a combination of surrogate entry assays and live virus, we demonstrate that, in addition to human angiotensin-converting enzyme 2 (ACE2), the Spike glycoprotein of SARS-CoV-2 has a broad host tropism for mammalian ACE2 receptors, despite divergence in the amino acids at the Spike receptor binding site on these proteins. Of the 22 different hosts we investigated, ACE2 proteins from dog, cat, and cattle were the most permissive to SARS-CoV-2, while bat and bird ACE2 proteins were the least efficiently used receptors. The absence of a significant tropism for any of the 3 genetically distinct bat ACE2 proteins we examined indicates that SARS-CoV-2 receptor usage likely shifted during zoonotic transmission from bats into people, possibly in an intermediate reservoir. Comparison of SARS-CoV-2 receptor usage to the related coronaviruses SARS-CoV and RaTG13 identified distinct tropisms, with the 2 human viruses being more closely aligned. Finally, using bioinformatics, structural data, and targeted mutagenesis, we identified amino acid residues within the Spike–ACE2 interface, which may have played a pivotal role in the emergence of SARS-CoV-2 in humans. The apparently broad tropism of SARS-CoV-2 at the point of viral entry confirms the potential risk of infection to a wide range of companion animals, livestock, and wildlife.

18 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
CCCarina Conceicao
Carina Conceicao
NTNazia Thakur
Nazia Thakur
SHStacey Human
Stacey Human
JKJames Kelly
James Kelly
LLLeanne Logan
Leanne Logan
DBDalan Bailey
Dalan Bailey
SARS-CoV-2 emerged in late 2019, leading to the COVID-19 pandemic that continues to cause significant global mortality in human populations. Given its sequence similarity to SARS-CoV, as well as related coronaviruses circulating in bats, SARS-CoV-2 is thought to have originated in Chiroptera species in China. However, whether the virus spread directly to humans or through an intermediate host is currently unclear, as is the potential for this virus to infect companion animals, livestock and wildlife that could act as viral reservoirs. Using a combination of surrogate entry assays and live virus we demonstrate that, in addition to human ACE2, the Spike glycoprotein of SARS-CoV-2 has a broad host tropism for mammalian ACE2 receptors, despite divergence in the amino acids at the Spike receptor binding site on these proteins. Of the twenty-two different hosts we investigated, ACE2 proteins from dog, cat and rabbit were the most permissive to SARS-CoV-2, while bat and bird ACE2 proteins were the least efficiently used receptors. The absence of a significant tropism for any of the three genetically distinct bat ACE2 proteins we examined indicates that SARS-CoV-2 receptor usage likely shifted during zoonotic transmission from bats into people, possibly in an intermediate reservoir. Interestingly, while SARS-CoV-2 pseudoparticle entry was inefficient in cells bearing the ACE2 receptor from bats or birds the live virus was still able to enter these cells, albeit with markedly lower efficiency. The apparently broad tropism of SARS-CoV-2 at the point of viral entry confirms the potential risk of infection to a wide range of companion animals, livestock and wildlife.

30 July 2019 in Viruses
Verified
Journal Article
Open access
PDF file
JKJames Kelly
James Kelly
SHStacey Human
Stacey Human
JAJoseph Alderman
Joseph Alderman
FJFatoumatta Jobe
Fatoumatta Jobe
LLLeanne Logan
Leanne Logan
DBDalan Bailey
Dalan Bailey
The measles virus (MeV), a member of the genus Morbillivirus, is an established pathogen of humans. A key feature of morbilliviruses is their ability to spread by virus–cell and cell–cell fusion. The latter process, which leads to syncytia formation in vitro and in vivo, is driven by the viral fusion (F) and haemagglutinin (H) glycoproteins. In this study, we demonstrate that MeV glycoproteins are sensitive to inhibition by bone marrow stromal antigen 2 (BST2/Tetherin/CD317) proteins. BST2 overexpression causes a large reduction in MeV syncytia expansion. Using quantitative cell–cell fusion assays, immunolabeling, and biochemistry we further demonstrate that ectopically expressed BST2 directly inhibits MeV cell–cell fusion. This restriction is mediated by the targeting of the MeV H glycoprotein, but not other MeV proteins. Using truncation mutants, we further establish that the C-terminal glycosyl-phosphatidylinositol (GPI) anchor of BST2 is required for the restriction of MeV replication in vitro and cell–cell fusion. By extending our study to the ruminant morbillivirus peste des petits ruminants virus (PPRV) and its natural host, sheep, we also confirm this is a broad and cross-species specific phenotype.

13 April 2022 in Journal of Virology
Verified
Journal Article
Open access
JKJames Kelly
James Kelly
JSJessica Swanson
Jessica Swanson
JNJoseph Newman
Joseph Newman
EGElisabetta Groppelli
Elisabetta Groppelli
NSNicola Stonehouse
Nicola Stonehouse
TTToby Tuthill
Toby Tuthill
To initiate infection, viruses must enter a host cell and deliver their genome into the appropriate location. The picornavirus family of small nonenveloped RNA viruses includes significant human and animal pathogens and is also a model to understand the process of cell entry.

Verified
Open access
PDF file
JKJames Kelly
James Kelly
GDGiann Kerwin Y. Dellosa
Giann Kerwin Y. Dellosa
JNJoseph Newman
Joseph Newman
AMAdel A. M. Mohamed
Adel A. M. Mohamed
JAJulia Aniscenko
Julia Aniscenko
TTToby Tuthill
Toby Tuthill
Infection with rhinovirus (RV) is a frequent cause of the common cold and is also associated with more significant morbidity, including hospitalisation, in people with chronic lung disease. At present, there is no licensed RV vaccine or antiviral. There are over 150 RV strains classified into 3 species (RV-A, RV-B, RV-C), and approximately 100 of these have been characterised as distinct serotypes. There is no cross-protection between serotypes because of high diversity in immunodominant antigenic sites. This makes it impractical to create a broadly protective vaccine using traditional methods, involving whole capsids. An alternative strategy is to direct the immune response towards conserved but less dominant epitopes. The capsid protein VP4 is highly conserved within each RV species, and antibodies that target the N-terminal region of VP4 have previously been shown to be neutralising. Here, we investigate the immunogenicity of three RV N-terminal VP4 peptides of different sizes (spanning residues 1–15, 1–30, and 1–45) presented on SpyCatcher virus-like particles (VLPs). Neutralising antibodies were only induced against the shortest peptide. The neutralising epitope contained within the first 15 amino acids was antigenically and structurally different in the context of longer peptides. This indicates the conformation of the 1–15 region of VP4 is critical for inducing antibodies that neutralise by binding VP4 in the context of the virus particle. Therefore, correctly displayed VP4 peptides can recapitulate virus-like antigenicity. These findings improve our understanding of VP4 antigenicity and may inform the design of future RV vaccines. This work could also impact the design of other peptide vaccines, since a variable antigenic conformation is a common characteristic of pathogen-derived peptide targets.

5 June 2026 in Science Advances
Verified
Journal Article
Open access
DZDaming Zhou
Daming Zhou
AKAbhay Kotecha
Abhay Kotecha
JKJames Kelly
James Kelly
PHPeng-Nien Huang
Peng-Nien Huang
YCYi-Yin Chen
Yi-Yin Chen
DSDavid Ian Stuart
David Ian Stuart
EV-A71 has been responsible for recent severe HFMD outbreaks. We report structures for 12 potently neutralizing human anti–EV-A71 monoclonal antibody Fabs, alone and complexed with virus. Most recognize the native antigenic state with epitopes that span interfaces, together covering 85% of the capsid surface. The majority (8 of 12) bind the canyon, while the others cluster around the icosahedral two- and threefold axes. Blocking SCARB2 receptor binding likely contributes to neutralization for all, and a subset induces empty particles. A predominant gene family (IGHV4-39) does not dictate a common binding pose. Long CDR-H3 loops are frequently key to binding, especially at the canyon, suggesting that antigenicity data based on antibodies with shorter CDR3s (e.g., murine) may be misleading. This dataset reveals neutralization mechanisms for recently circulating EV-A71 genotypes, which will inform immunotherapies. We demonstrate synergy in vitro between canyon binding and both two- and threefold binding antibodies to increase neutralization potency.